Literature DB >> 31733691

Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease.

Karlo J Lizarraga1, Susan H Fox2, Antonio P Strafella2, Anthony E Lang2.   

Abstract

Psychotic and compulsive symptoms in Parkinson disease are highly prevalent and associated with poor outcomes and greater caregiver burden. When acute, delirium should be ruled out or treated accordingly. When chronic, comorbid systemic illnesses, dementia, and psychiatric disorders should be considered. Reduction and discontinuation of anticholinergics, amantadine, dopamine agonists, and levodopa as tolerated, as well as adjunctive clozapine or quetiapine are frequently effective to manage Parkinson disease psychosis. Pimavanserin appears effective but is not widely available, and more experience is needed. Dopamine agonist discontinuation is usually successful for impulse control disorders, but requires frequent monitoring, documentation, and caregiver involvement.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Compulsions; Delirium; Delusions; Dopamine dysregulation syndrome; Hallucinations; Impulse control disorders; Parkinson disease; Psychosis

Mesh:

Year:  2019        PMID: 31733691     DOI: 10.1016/j.cger.2019.09.004

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  3 in total

1.  Prevalence and Cumulative Incidence of Caregiver-Reported Aggression in Advanced Parkinson Disease and Related Disorders.

Authors:  Zachary A Macchi; Janis Miyasaki; Maya Katz; Nicholas Galifianakis; Stefan Sillau; Benzi M Kluger
Journal:  Neurol Clin Pract       Date:  2021-12

Review 2.  Psychosis in Parkinson's disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges.

Authors:  John L Waddington
Journal:  Acta Pharmacol Sin       Date:  2020-03-05       Impact factor: 6.150

3.  Factors affecting hallucinations in patients with delirium.

Authors:  Masako Tachibana; Toshiya Inada; Masaru Ichida; Norio Ozaki
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.